SCHEMBL15212192

SCHEMBL15212192

CN(C)CCC(N)OC(N)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.37
CHRNA4 P43681 2/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
LMNA P02545 2/20 0.35
CHRM2 P08172 2/20 0.35
CHRM4 P08173 2/20 0.35
CHRM5 P08912 2/20 0.35
CHRM1 P11229 2/20 0.35
CHRM3 P20309 2/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
MAPT P10636 1/20 0.34
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
UTS2R Q9UKP6 4/20 0.31
ANPEP P15144 1/20 0.31
ALOX15 P16050 1/20 0.30
MBTD1 Q05BQ5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9617900 0.85 CHRNB2 (0.34) CHRNB2CHRNA4CHRNB4CHRNA3LMNA
SCHEMBL14782557 0.83 TSHR (0.36) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL15212136 0.76 CHRM2 (0.37) LMNACHRM2CHRM4CHRM5CHRM1
SCHEMBL27703023 0.76
SCHEMBL4451108 0.75 CTSK (0.35) CHRNB2CHRNA4CHRNB4CHRNA3LMNA
Hydrochloric Acid SCHEMBL28863116 0.73 CTSK (0.34) CHRNB2CHRNA4CHRNB4CHRNA3LMNA
SCHEMBL1010771 0.73
SCHEMBL16290200 0.72 CA2 (0.47) LMNACHRM2CHRM4CHRM5CHRM1
SCHEMBL11872398 0.72 DNM1 (0.55) LMNACYP2C9TSHRMAPT
SCHEMBL4603896 0.71 NOS2 (0.40) CHRNB2CHRNA4CHRNB4CHRNA3CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015184326-A1 CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS CERULEAN PHARMA INC. (US) 2015-12-03 WO disclosed
WO-2015057847-A1 CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS CERULEAN PHARMA INC. (US) 2015-04-23 WO disclosed
EP-2817345-A1 CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS Cerulean Pharma Inc. (US) 2014-12-31 EP disclosed
US-20140037573-A1 CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS CERULEAN PHARMA INC (US) 2014-02-06 US disclosed
WO-2013126564-A1 CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS CERULEAN PHARMA INC. (US) 2013-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140037573-A1 CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS SYNCRIP, EXOSC5, EXOSC9 CHRNB2 3314/4885CHRNA4 4215/4885CHRNB4 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.